Tirzepatide: what it is and what the evidence says
A synthetic 39-amino-acid peptide that activates both the GIP and GLP-1 receptors, the two gut hormones that regulate appetite, stomach emptying, and the insulin response to glucose. A fatty acid chain binds it to albumin and extends its action.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilizing stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Weight loss, glucose control, cardiometabolic health.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
It is backed by large phase 3 trials. The SURMOUNT program recorded mean weight losses of up to 21% at 72 weeks, and the SURPASS program supported it in type 2 diabetes. It was superior to Semaglutide in two head-to-head comparisons (SURPASS-2 and SURMOUNT-5), and SURPASS-CVOT showed cardiovascular non-inferiority against dulaglutide.
The limitation that matters most
In obesity without diabetes there is not yet a completed cardiovascular events trial; SURMOUNT-MMO is still ongoing. Weight tends to return after stopping (SURMOUNT-4), and the long-term course of muscle mass and bone still needs to be better understood.
Regulatory status
Approved by the FDA as Mounjaro for type 2 diabetes (2022; from 10 years of age in 2025) and to reduce major cardiovascular events in adults with type 2 diabetes at high risk (August 2026), and as Zepbound for chronic weight management (2023) and obstructive sleep apnea in adults with obesity (2024). In the European Union, Mounjaro is authorized for type 2 diabetes and weight management. It is not prohibited by WADA, which has tracked it in its Monitoring Program since 2026.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
Digestive effects cluster at the start and at each step up, and weight loss can take muscle with it if protein and strength training fall short. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2, and it calls for attention to the pancreas, gallbladder, and hydration.
It is a prescription medicine that is started and adjusted with a physician, with particular care if you are on insulin or sulfonylureas, or if there is pregnancy, a history of pancreatitis, or digestive disease.
What this page cannot give you
A reference page can take you this far. You know what Tirzepatide is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Tirzepatide Once Weekly for the Treatment of Obesityhuman N Engl J Med · 2022 · PMID 35658024 →
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabeteshuman N Engl J Med · 2021 · PMID 34170647 →
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialhuman Lancet · 2023 · PMID 37385275 →
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trialhuman JAMA · 2024 · PMID 38078870 →
- Tirzepatide for Obesity Treatment and Diabetes Preventionhuman N Engl J Med · 2025 · PMID 39536238 →
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesityhuman N Engl J Med · 2025 · PMID 40353578 →
- Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Diabetologia · 2024 · PMID 38613667 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Tirzepatide or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Tirzepatide?
A synthetic 39-amino-acid peptide that activates both the GIP and GLP-1 receptors, the two gut hormones that regulate appetite, stomach emptying, and the insulin response to glucose. A fatty acid chain binds it to albumin and extends its action. It is studied within the area of metabolic.
Is there human evidence for Tirzepatide?
It is backed by large phase 3 trials. The SURMOUNT program recorded mean weight losses of up to 21% at 72 weeks, and the SURPASS program supported it in type 2 diabetes. It was superior to Semaglutide in two head-to-head comparisons (SURPASS-2 and SURMOUNT-5), and SURPASS-CVOT showed cardiovascular non-inferiority against dulaglutide.
Is it approved by any health agency?
Approved by the FDA as Mounjaro for type 2 diabetes (2022; from 10 years of age in 2025) and to reduce major cardiovascular events in adults with type 2 diabetes at high risk (August 2026), and as Zepbound for chronic weight management (2023) and obstructive sleep apnea in adults with obesity (2024). In the European Union, Mounjaro is authorized for type 2 diabetes and weight management. It is not prohibited by WADA, which has tracked it in its Monitoring Program since 2026.
What is the dose of Tirzepatide?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Tirzepatide is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.